Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study

14Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Objective: The effectiveness and safety of aprotinin use in cardiac surgery have been questioned. More data reflecting everyday clinical practice from large-scale, unselected populations are needed. We compared the effectiveness and safety of aprotinin in cardiac surgery with those of tranexamic acid in a follow-up study using the population-based Danish health-care databases. Methods: We identified a total of 3535 patients who underwent cardiac surgery at the Aarhus University Hospital, Skejby, between 1 January 2003 and 31 December 2006; of these, 635 patients were treated with aprotinin and 2900 with tranexamic acid. We used propensity score matching to match aprotinin-treated patients with tranexamic-acid-treated patients in a 1:1 ratio, followed by Poisson regression analysis to compute relative risks (RRs). Results: Patients treated with aprotinin had more severe preoperative risk profiles than the tranexamic-acid-treated patients. The rates of postoperative drainage and transfusion of red blood cells were similar in the two groups, whereas the aprotinin group received plasma (adjusted RR = 1.39; 95% confidence interval (CI): 1.15-1.68) and platelets (adjusted RR = 1.47; 95% CI: 1.19-1.81) more frequently than the tranexamic acid group. There were no statistically significant differences in risks of re-operation due to bleeding (adjusted RR = 1.22; 95% CI: 0.84-1.78), 30-day mortality (adjusted RR = 1.03; 95% CI: 0.69-1.54), acute myocardial infarction (adjusted RR = 1.06; 95% CI: 0.69-1.64), stroke (adjusted RR = 1.36; 95% CI: 0.75-2.44) or composite major event (adjusted RR = 1.14; 95% CI: 0.87-1.50) between the two groups. However, patients who received aprotinin had an increased risk of postoperative dialysis (adjusted RR = 1.76; 95% CI: 1.15-2.70). Conclusions: Aprotinin treatment was associated with an increased use of plasma and platelet transfusion and an increased risk for postoperative dialysis, but not with other adverse outcomes, including short-term mortality. © 2009 European Association for Cardio-Thoracic Surgery.

Cite

CITATION STYLE

APA

Jakobsen, C. J., Søndergaard, F., Hjortdal, V. E., & Johnsen, S. P. (2009). Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study. European Journal of Cardio-Thoracic Surgery, 36(5), 863–868. https://doi.org/10.1016/j.ejcts.2009.05.040

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free